Research progress and review strategies of monkeypox vaccines in China and abroad
WU Ying-qi
LIU Ying
SHAO Yi-ming
Abstract：Mpox is an acute infectious disease caused by the monkeypox virus.Most of the cases primarily distributed in African countries.Since the global dissemination of the monkeypox outbreak in 2022,the World Health Organization(WHO)has declared twice that it has become a public health emergency of international concern.This highlights the urgent need for preventive vaccines,however currently,no monkeypox vaccine has been approved in China.It is necessary to expedite the clinical research and approval of domestically produced vaccines to meet the demands of the prevention and control of monkeypox epidemic in China.This article presents a summary of the current research and development progress of monkeypox vaccines in China and abroad.It also collates the strategies and bases for the review of the clinical efficacy of monkeypox vaccines by the regulatory authorities of the United States,Europe,Japan and other countries or regions,as well as the WHO.Additionally,we discuss the research and development,as well as review strategies of domestically produced monkeypox vaccines,aiming to promote the development and approval of monkeypox vaccines in China.
Keywords：monkrypox vaccinesmallpox vaccinemRNA vaccinesubunit vaccinereview strategy
Publication Date：2025-08-03
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 1709-1715 )